available for iOS, Android & web
February 05, 2015
December 02, 2014
November 18, 2014
October 12, 2014
Akynzeo combines palonosetron and netupitant
August 15, 2014
Rejected for use before chemotherapy
September 26, 2013
Oncotype DX to help make decisions on chemotherapy
August 15, 2013
Endorsing those clinically and cost effective
July 02, 2013
A greater number of patients with breast cancer could be spared chemotherapy to reduce their risk of the disease returning, after UK scientists developed a more accurate genetic test to determine the likelihood of recurrence.
June 21, 2013
Celgene Corp has presented mid-stage data from a pair of trials which demonstrate the promise of using its myeloma blockbuster Revlimid in combination with Roche and Biogen Idec's big-selling monoclonal antibody Rituxan for various non-Hodgkin’s lymphomas
February 19, 2013
New draft guidance from NICE recommends that the NHS should use one test, Oncotype DX, to guide decisions about the use of chemotherapy in people with early breast cancer, but not three others.
Recruitment agencies provide the unique bridge to [more]...
International Clinical Researcher of the Year 2016
Book your tickets today!
PharmaTimes 2015 Copyright | RSS Feed Subscriptions